Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Embrex
Durham, North Carolina, USAembrex.com ↗
- Ownership
- Private
- Employees
- ~300
- Development stage
- Other
01
Overview
Embrex is a pioneer in poultry biotechnology, best known for developing the Inovoject system, the first commercially viable in-ovo (in-the-egg) injection technology. This system automates the vaccination of chick embryos, significantly improving efficiency and bird health compared to post-hatch methods. The company's portfolio includes a range of biological products and vaccines targeting major avian diseases such as Marek's disease and coccidiosis. Acquired by Pfizer in 2006, Embrex's technologies now form a core part of Zoetis's poultry health division. The company's focus remains on enhancing global food production through advanced veterinary diagnostics and automated delivery systems.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineDevice
- Industry
- Veterinary
Beyond the preview
Go deeper on Embrex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Embrex.